
News
October 2022 Exhalix files a patent application # 63/420454 in the U.S. on ReLIS™/HEALS™ with the USPTO.
September 2022 Publication on early clinical results of TAGS appears in the Journal of Sensing and Bio-Sensing Research, https://www.sciencedirect.com/science/article/pii/S2214180422000526.
August 2022 Exhalix receives a Phase I SBIR grant from National Institute of Aging to develop and test in collaboration with the UNM School of Medicine a prototype of ReLIS for at-risk surgical wound therapy.
July 2022 Exhalix receives EU approval of its patent on TAGS.
June 2022 Exhalix receives notification of funding from the National Heart Lung and Blood Institute Commercialization Readiness Pilot (CRP) program to further advance TAGS productization and clinical trials in collaboration with the UNM School of Medicine for application in diagnosis of peripheral artery disease.
June 2021 Exhalix receives a Phase I SBIR grant from National Institute of General Medical Sciences to develop and test in collaboration with the UNM School of Medicine a prototype of the HEALS technology for treatment of hard-to-heal chronic wounds.
December 2020 Exhalix is granted US Patent # 10,856,790 on “Transdermal Sampling Strip and Method for Analyzing Transdermally Emitted Gases.”
Learn More
Additional Information
1. S. Virani, A. Alonso, E. Benjamin, M. Bittencourt, C. Callaway, A. Carson and e. al., “Heart disease and stroke statistics—2020 update: a report from the American Heart Association,” Circulation, vol. 141, no. 9, pp. e139-e596, 2020. Read Here
2. CDC, “Peripheral Arterial Disease (PAD),” 8 September 2020. [Online] Read Here
3. A. C. Salisbury and D. J. Cohen, “Economic Analysis in Peripheral Artery Disease,” Endovascular Today, vol. 15, no. 10, pp. 53-57, 2016. Read Here
4. C. Walker, “THE SAGE GROUP Releases New Estimates for the United States Prevalence and Incidence of Peripheral Artery Disease (PAD) and Critical Limb Ischemia (CLI),” Vascular Disease Management, 25 October 2016. [Online] Read Here [Accessed 15 February 2021].
5. J. A. Barnes, M. A. Eid, M. A. Creager and P. P. Goodney, “Epidemiology and Risk of Amputation in Patients With Diabetes Mellitus and Peripheral Artery Disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 40, pp. 1808-1817, 2020. Read Here
6. H. Kimura, “Production and physiological effects of hydrogen sulfide,” Antioxid Redox Signal, vol. 20, no. 5, pp. 783-793, 2014. Read Here
7. R. Wang, “Physiological implications of hydrogen sulfide: a whiff exploration that blossomed,” Physiol Rev, vol. 92, pp. 791-896, 2012. Read Here
8. L. Li, P. Rose and P. K. Moore, “Hydrogen sulfide and cell signaling,” Annu Rev Pharmacol Toxicol , vol. 51, pp. 169-187, 2011. Read Here
9. A. K. Mustafa, M. M. Gadalla and S. H. Snyder, “Signaling by Gasotransmitters,” Sci Signal , vol. 2, no. 68, p. re2, 2009. Read Here
10. J. Wallace and R. Wang, “Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter,” Nature Rev Drug Discov, vol. 14, pp. 329-345, 2015. Read Here
11. J. Candela, M. Baker and T. Koch, “Is Hydrogen Sulfide The Missing Link In Diabetic Wound Care?,” Podiatry Today, vol. 33, no. 8, 2020. [Online] Read Here
12. A. R. Jensen, N. A. Drucker, S. Khaneki, M. J. Ferkowicz, M. C. Yoder, E. R. DeLeon, K. R. Olson and T. A. Markel, “Hydrogen Sulfide: A Potential Novel Therapy for the Treatment of Ischemia,” Shock, vol. 48, no. 5, pp. 511-524, 2017. Read Here
13. J. L. Wallace, G. P. Ferraz and M. N. Muscara, “Hydrogen Sulfide: An Endogenous Mediator of Resolution of Inflammation and Injury,” Antioxidants & Redox Signaling, vol. 17, no. 1, pp. 58-67, 2012. Read Here
14. N. Kanagy, C. Szabo and A. Papapetropoulos, “Vascular Biology of Hydrogen Sulfide,” Am J Physiol Cell Physiol, vol. 312, p. C537–C549, 2017. Read Here
15. G. Wang, W. Li, Q. Chen, Y. Jiang, X. Lu and X. Zhao, “Hydrogen sulfide accelerates wound healing in diabetic rats,” Int J Clin Exp Pathol, vol. 8, no. 5, pp. 5097-5104, 2015. Read Here
16. D. J. Lefer, “A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide,” Proc. Natl. Acad. Sci., 2007 Nov 13;104(46):17907-8. Read Here
17. B. L. Predmore, D. J. Lefer, and G. Gojon, “Hydrogen Sulfide in Biochemistry and Medicine,” Antioxid Redox Signal. 2012 Jul 1; 17(1): 119–140. Read Here
18. Y. Han, Q. Shang, J. Yao, and Y. Ji, “Hydrogen sulfide: a gaseous signaling molecule modulates tissue homeostasis: implications in ophthalmic diseases,” Cell Death & Disease, 2019, V 10, No. 293. Read Here
19. S. A. Coavoy-Sánchez, S. K. P. Costa, M. N. Muscará, “Hydrogen sulfide and dermatological diseases,” Br J Pharmacol, 2020 Feb;177(4):857-865. Read Here
20. Y. Zhang, Z.-H. Tang, Z.g Ren, S.-L. Qu, M.-H. Liu, L.-S. Liu, Z.-S. Jiang, “Hydrogen Sulfide, the Next Potent Preventive and Therapeutic Agent in Aging and Age-Associated Diseases,” Molecular and Cellular Biology, 2013, Volume 33 Number 6, pp. 1104 –1113. Read Here
Disclaimer
The research results provided in this website are produced by grants supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under SBIR Award HL121871-01 through -04. The content is solely the responsibility of Exhalix and does not necessarily represent the official views of the National Institutes of Health. The research is conducted following Financial Conflict of Interest (FCOI) policy provided in the attached document.
CAUTION: TAGS™ is an investigational device. Limited by Federal law to investigational use.
TAGS™, HEALS™, and ReLIS™ are trademarks of Exhalix, LLC.